Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405

RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity

(2015) Brandon L. Probst et al.   PLoS One

Myeloid Lineage-Specific Deletion of Antioxidant System Enhances Tumor Metastasis

(2014) K. Hiramoto et al.   Cancer Prevention Research

Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment

(2014) Yan-Yang Wang et al.   Molecular Cancer

Effect of Redox Modulating NRF2 Activators on Chronic Kidney Disease

(2014) Bo-hyun Choi et al.   MOLECULES

Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO

(2014) Anne Cleasby et al.   PLoS One

Oral Administration of a Gemini Vitamin D Analog, a Synthetic Triterpenoid and the Combination Prevents Mammary Tumorigenesis Driven by ErbB2 Overexpression

(2013) J. Y. So et al.   Cancer Prevention Research

Cancer-Derived Mutations in KEAP1 Impair NRF2 Degradation but not Ubiquitination

(2013) B. E. Hast et al.   CANCER RESEARCH

BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety

(2013) Robert J. Fox et al.   CURRENT MEDICAL RESEARCH AND OPINION

Synthetic Triterpenoids Can Protect against Toxicity without Reducing the Efficacy of Treatment with Carboplatin and Paclitaxel in Experimental Lung Cancer

(2013) Karen T. Liby   Dose-Response

The emerging role of the Nrf2-Keap1 signaling pathway in cancer

(2013) M. C. Jaramillo et al.   GENES & DEVELOPMENT

Insight into the Intermolecular Recognition Mechanism between Keap1 and IKKβ Combining Homology Modelling, Protein-Protein Docking, Molecular Dynamics Simulations and Virtual Alanine Mutation

(2013) Zheng-Yu Jiang et al.   PLoS One

Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex

(2013) L. Baird et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Keap1: One stone kills three birds Nrf2, IKKβ and Bcl-2/Bcl-xL

(2012) Hui Tian et al.   CANCER LETTERS

The Synthetic Triterpenoid CDDO-Methyl Ester Delays Estrogen Receptor-Negative Mammary Carcinogenesis in Polyoma Middle T Mice

(2012) K. Tran et al.   Cancer Prevention Research

The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II–induced contraction of glomerular mesangial cells

(2012) Yanfeng Ding et al.   KIDNEY INTERNATIONAL

The cytoprotective role of the Keap1–Nrf2 pathway

(2011) Liam Baird et al.   ARCHIVES OF TOXICOLOGY

Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis

(2011) Arie Neymotin et al.   FREE RADICAL BIOLOGY AND MEDICINE

New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative Stress

(2011) Michael B. Sporn et al.   JOURNAL OF NATURAL PRODUCTS

Genetic Disruption of KEAP1/CUL3 E3 Ubiquitin Ligase Complex Components is a Key Mechanism of NF-KappaB Pathway Activation in Lung Cancer

(2011) Kelsie L. Thu et al.   Journal of Thoracic Oncology

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis

(2011) Gina M. DeNicola et al.   NATURE

Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

(2011) Pablo E. Pergola et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gain of Nrf2 Function in Non-Small-Cell Lung Cancer Cells Confers Radioresistance

(2010) Anju Singh et al.   ANTIOXIDANTS & REDOX SIGNALING

Synthetic Triterpenoids Prolong Survival in a Transgenic Mouse Model of Pancreatic Cancer

(2010) K. T. Liby et al.   Cancer Prevention Research

INrf2 (Keap1) targets Bcl-2 degradation and controls cellular apoptosis

(2010) S K Niture et al.   CELL DEATH AND DIFFERENTIATION

Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer

(2010) S. Nagaraj et al.   CLINICAL CANCER RESEARCH

Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease

(2010) Cliona Stack et al.   FREE RADICAL BIOLOGY AND MEDICINE

Loss of Kelch-Like ECH-Associated Protein 1 Function in Prostate Cancer Cells Causes Chemoresistance and Radioresistance and Promotes Tumor Growth

(2010) P. Zhang et al.   MOLECULAR CANCER THERAPEUTICS

Triterpenoids CDDO-Methyl Ester or CDDO-Ethyl Amide and Rexinoids LG100268 or NRX194204 for Prevention and Treatment of Lung Cancer in Mice

(2009) K. Liby et al.   Cancer Prevention Research

Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice

(2009) Melinda S. Yates et al.   CARCINOGENESIS

Nrf2: friend or foe for chemoprevention?

(2009) T. W. Kensler et al.   CARCINOGENESIS

KEAP1 E3 Ligase-Mediated Downregulation of NF-κB Signaling by Targeting IKKβ

(2009) Dung-Fang Lee et al.   MOLECULAR CELL

NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer

(2009) John D. Hayes et al.   TRENDS IN BIOCHEMICAL SCIENCES

Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues

(2008) Rui Wang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Triterpenoid CDDO-Methyl Ester Inhibits the Janus-Activated Kinase-1 (JAK1)->Signal Transducer and Activator of Transcription-3 (STAT3) Pathway by Direct Inhibition of JAK1 and STAT3

(2008) R. Ahmad et al.   CANCER RESEARCH

Loss of Keap1 Function Activates Nrf2 and Provides Advantages for Lung Cancer Cell Growth

(2008) T. Ohta et al.   CANCER RESEARCH

RNAi-Mediated Silencing of Nuclear Factor Erythroid-2-Related Factor 2 Gene Expression in Non-Small Cell Lung Cancer Inhibits Tumor Growth and Increases Efficacy of Chemotherapy

(2008) A. Singh et al.   CANCER RESEARCH

Physiological Significance of Reactive Cysteine Residues of Keap1 in Determining Nrf2 Activity

(2008) T. Yamamoto et al.   MOLECULAR AND CELLULAR BIOLOGY

Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy

(2008) T. Shibata et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA